June 08, 2006
ImmunoGen, Inc. to Present at Needham & Company, LLC's Fifth Annual Biotechnology and Medical Technology Conference

CAMBRIDGE, Mass.--(BUSINESS WIRE)--June 8, 2006--ImmunoGen, Inc. (Nasdaq: IMGN) today announced that it will present at Needham & Company, LLC's Fifth Annual Biotechnology and Medical Technology Conference, which is scheduled to take place June 14 - 15, 2006 at the New York Palace Hotel in New York City. The 25-minute presentation is to begin at 2:00 pm ET on Thursday, June 15, 2006, and will be given by Mitchel Sayare, ImmunoGen Chairman and CEO.

A live webcast of the presentation may be accessed through the "Investor Relations" section of the ImmunoGen website, Afterwards, a replay of the presentation will be available at the same location until June 22, 2006.

About ImmunoGen, Inc.

ImmunoGen, Inc. develops targeted anticancer biopharmaceuticals. The Company's proprietary Tumor-Activated Prodrug (TAP) technology uses tumor-targeting antibodies to deliver a potent cell-killing agent specifically to cancer cells. Four TAP compounds are in clinical testing - huN901-DM1 and huC242-DM4, which are wholly owned by ImmunoGen, and AVE9633 and trastuzumab-DM1, which are in development by the sanofi-aventis Group and Genentech, respectively. The sanofi-aventis Group, Genentech, Centocor, Biogen Idec, Millennium Pharmaceuticals, Inc., Boehringer Ingelheim, and Amgen (formerly Abgenix) have licensed the right to develop and/or test TAP compounds to specific targets; ImmunoGen also has a broader collaboration with the sanofi-aventis Group.

CONTACT: Investors:
ImmunoGen, Inc.
Carol Hausner, 617-995-2500

SOURCE: ImmunoGen, Inc.



The "Yes" link below will take you out of the AbbVie family of websites.

Links which take you out of the AbbVie worldwide websites are not under the control of AbbVie, and AbbVie is not responsible for the contents of any such site or any further links from such site. AbbVie is providing these links to you only as a convenience and the inclusion of any link does not imply endorsement of the linked site by AbbVie.

The Internet site that you have requested may not be optimized to your screen size.

Do you wish to leave this site?